Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions
High-Dose Consolidation RT Shows Limited Benefit in DLBCL
Key clinical point: High-dose consolidation radiation therapy (RT) may be unnecessary for patients with diffuse large B-cell lymphoma (DLBCL) with osseous involvement who achieve a complete response to first-line chemotherapy.
Major finding: At 5 years, freedom from local recurrence using a median dose of 29 Gy was 96%, while overall and disease-free survival were 86% and 76%, respectively.
Study details: A retrospective case series of 51 patients with DLBCL who had osseous involvement.
Disclosures: There was no outside funding for the study. The authors reported having no conflicts of interest.
Lee JW et al. Adv Radiat Oncol. 2019 Mar 30;4(3):507-12. doi: 10.1016/j.adro.2019.03.010.